Targeting poly(ADP-ribose) glycohydrolase (PARG) is being explored as anti-cancer therapeutic strategy, and PARG loss may also contribute to resistance to PARP inhibitor (PARPi) treatment. This evidence concerns the gene PARP1 and cancer.